

## Special Issue

# Hereditary Metabolic Diseases: The Biological Clock and Innovative Therapies

### Message from the Guest Editors

Hereditary metabolic diseases constitute a variety of congenital pathologies caused by genetic defects that have an impact on metabolism, especially within the cells of the liver. There are hundreds of hereditary metabolic diseases, caused by genetic defects of various kinds. New medical treatment strategies and advanced therapies represent an important and urgent need. Advanced therapies are innovative treatment tools and strategies that offer new opportunities for the treatment of inherited metabolic diseases for which conventional treatments have proved inadequate. Advanced therapies contain genetic material, stem cells, or tissue-engineered modified cells/tissues to be used to repair, regenerate, or replace human tissue. These therapies offer the possibility of personalizing the treatment and reducing the side effects. For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: hereditary metabolic diseases, the biological clock, innovative therapies, stem-cell therapy, regenerative medicine, and cell/tissue engineering. We look forward to receiving your contributions.

### Guest Editors

Prof. Dr. Gianluigi Mazzocchi

Department of Medical Sciences, Division of Internal Medicine and Chronobiology Laboratory, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy

Prof. Dr. Roberto Tarquini

Division of Internal Medicine I, San Giuseppe Hospital, 50053 Empoli, Italy

### Deadline for manuscript submissions

closed (31 January 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/132643](https://mdpi.com/si/132643)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).